Kyntra Bio (KYNB) Equity Average (2016 - 2025)
Historic Equity Average for Kyntra Bio (KYNB) over the last 11 years, with Q3 2025 value amounting to -$120.0 million.
- Kyntra Bio's Equity Average rose 4957.53% to -$120.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$120.0 million, marking a year-over-year increase of 4957.53%. This contributed to the annual value of -$214.9 million for FY2024, which is 9048.9% down from last year.
- As of Q3 2025, Kyntra Bio's Equity Average stood at -$120.0 million, which was up 4957.53% from -$219.9 million recorded in Q2 2025.
- Kyntra Bio's Equity Average's 5-year high stood at $415.9 million during Q1 2021, with a 5-year trough of -$238.0 million in Q3 2024.
- Its 5-year average for Equity Average is -$5.2 million, with a median of -$75.6 million in 2023.
- Its Equity Average has fluctuated over the past 5 years, first plummeted by 155547.01% in 2023, then surged by 4957.53% in 2025.
- Kyntra Bio's Equity Average (Quarter) stood at $287.1 million in 2021, then crashed by 95.68% to $12.4 million in 2022, then crashed by 1555.47% to -$180.7 million in 2023, then fell by 29.87% to -$234.6 million in 2024, then surged by 48.85% to -$120.0 million in 2025.
- Its last three reported values are -$120.0 million in Q3 2025, -$219.9 million for Q2 2025, and -$221.2 million during Q1 2025.